{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:00:39Z","timestamp":1790791239581,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Around 12% of hereditary disease-causing mutations are in-frame nonsense mutations. The expression of genes containing nonsense mutations potentially leads to the production of truncated proteins with residual or virtually no function. However, the translation of transcripts containing premature stop codons resulting in full-length protein expression can be achieved using readthrough agents. Among them, only ataluren was approved in several countries to treat nonsense mutation Duchenne muscular dystrophy (DMD) patients. This review summarizes ataluren\u2019s journey from its identification, via first in vitro activity experiments, to clinical trials in DMD, cystic fibrosis, and aniridia. Additionally, data on its pharmacokinetics and mechanism of action are presented. The range of diseases with underlying nonsense mutations is described for which ataluren therapy seems to be promising. What is more, experiments in which ataluren did not show its readthrough activity are also included, and reasons for their failures are discussed.<\/jats:p>","DOI":"10.3390\/ph14080785","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T09:03:53Z","timestamp":1628499833000},"page":"785","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Ataluren\u2014Promising Therapeutic Premature Termination Codon Readthrough Frontrunner"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-7527","authenticated-orcid":false,"given":"Sylwia","family":"Michorowska","sequence":"first","affiliation":[{"name":"Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/nar\/22.8.1327","article-title":"Mutations to nonsense codons in human genetic disease: Implications for gene therapy by nonsense suppressor tRNAs","volume":"22","author":"Atkinson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Morais, P., Adachi, H., and Yu, Y.T. (2020). Suppression of nonsense mutations by new emerging technologies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124394"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/cdd.2015.53","article-title":"TP53: An oncogene in disguise","volume":"22","author":"Soussi","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Michorowska, S., Giebu\u0142towicz, J., Wolinowska, R., Konopka, A., Wilkaniec, A., Krajewski, P., Bulska, E., and Wroczy\u0144ski, P. (2019). Detection of ALDH3B2 in Human Placenta. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246292"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/ijmm.2014.1809","article-title":"Therapeutic suppression of premature termination codons: Mechanisms and clinical considerations (Review)","volume":"34","author":"Karijolich","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmg.2006.04.003","article-title":"Translational readthrough induction of pathogenic nonsense mutations","volume":"49","author":"Kellermayer","year":"2006","journal-title":"Eur. J. Med. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.micro.61.080706.093323","article-title":"Peptide release on the ribosome: Mechanism and implications for translational control","volume":"62","author":"Youngman","year":"2008","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-med-120611-144851","article-title":"Ataluren as an agent for therapeutic nonsense suppression","volume":"64","author":"Peltz","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/brv.12657","article-title":"Deciphering the molecular mechanism of stop codon readthrough","volume":"96","author":"Palma","year":"2021","journal-title":"Biol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1093\/hmg\/ddt120","article-title":"The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis","volume":"22","author":"Miller","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/jcb.22979","article-title":"Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations","volume":"112","author":"Dranchak","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"N\u00f3brega, C., Mendon\u00e7a, L., and Matos, C.A. (2020). Gene Therapy Strategies: Gene Augmentation. A Handbook of Gene and Cell Therapy, Springer International Publishing.","DOI":"10.1007\/978-3-030-41333-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.2010.067","article-title":"PTC124-mediated translational readthrough of a nonsense mutation causing usher syndrome type 1C","volume":"22","author":"Goldmann","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/emmm.201201438","article-title":"A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation","volume":"4","author":"Goldmann","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_16","unstructured":"European Medicines Agency (2021, April 12). Translarna Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/translarna-epar-product-information_en.pdf."},{"key":"ref_17","unstructured":"PTC Therapeutics (2021, April 12). PTC Therapeutics Receives Conditional Approval in the European Union for Translarna for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. Available online: http:\/\/ir.ptcbio.com\/releasedetail.cfm?releaseid=863914."},{"key":"ref_18","unstructured":"European Medicines Agency (2021, May 02). Translarna: EPAR-Procedural Steps Taken and Sceintific Information after Authorisation. Available online: www.ema.europa.eu\/contact."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and effectiveness of ataluren: Comparison of results from the STRIDE Registry and CINRG DMD Natural History Study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_21","unstructured":"(2021, July 05). PTC Announces TranslarnaTM Approval in Russia for the Treatment of Duchenne Muscular Dystrophy. Available online: https:\/\/www.prnewswire.com\/news-releases\/ptc-announces-translarna-approval-in-russia-for-the-treatment-of-duchenne-muscular-dystrophy-301186438.html."},{"key":"ref_22","unstructured":"(2021, July 05). PTC Therapeutics-Approved Medicines. Available online: https:\/\/www.ptcbio.com\/our-pipeline\/approved-medicines\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/hmg\/dds223","article-title":"Read-through compound 13 restores dystrophin expression and improves muscle function in the MDX mouse model for duchenne muscular dystrophy","volume":"21","author":"Kayali","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","unstructured":"Welch, E.M., Zhuo, J., Tomizawa, Y., Friesen, W., Branstrom, A., Hwang, S., Babiak, J., Miller, L.L., and Peltz, S.W. (2005). Characterization of PTC124 Activity, Specificity, and Mechanism of Action for Nonsense Mutation Suppression. Neurology, Lippincott Williams & Wilkins."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","article-title":"Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsensemediated zebrafish model","volume":"25","author":"Moosajee","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bbrc.2012.09.133","article-title":"Treatment of a methylmalonyl-CoA mutase stopcodon mutation","volume":"427","author":"Buck","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","unstructured":"Barton, E., Zadel, M., Welch, E., Trotta, C., Paushkin, M., Patel, M., Zhuo, J., Tomizawa, Y., Weetall, M., and Northcutt, V. (2005). PTC124 Nonsense Mutation Supression Therapy of Duchenne Muscular Dystrophy (DMD). Neurology, Lippincott Williams & Wilkins."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13429","DOI":"10.7554\/eLife.13429","article-title":"Kinetics of initiating polypeptide elongation in an IRES-dependent system","volume":"5","author":"Zhang","year":"2016","journal-title":"eLife"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/acsmedchemlett.8b00472","article-title":"New in Vitro Assay Measuring Direct Interaction of Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery","volume":"9","author":"Ng","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2020599118","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms","volume":"118","author":"Nga","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Casimir","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Finkel, R.S., Flanigan, K.M., Wong, B., B\u00f6nnemann, C., Sampson, J., Sweeney, H.L., Reha, A., Northcutt, V.J., Elfring, G., and Barth, J. (2013). Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081302"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1096\/fj.13-240044","article-title":"Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment","volume":"28","author":"Li","year":"2014","journal-title":"FASEB J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00576","DOI":"10.1002\/prp2.576","article-title":"In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren","volume":"8","author":"Kong","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/dmd.119.089391","article-title":"Metabolism and disposition of ataluren after oral administration to mice, rats, dogs, and humans","volume":"48","author":"Kong","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200302000-00001","article-title":"Acyl glucuronide drug metabolites: Toxicological and analytical implications","volume":"25","author":"Shipkova","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100393","DOI":"10.1016\/j.dmpk.2021.100393","article-title":"Ataluren metabolism: Ataluren-O-1\u03b2-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human","volume":"38","author":"Ma","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cpdd.645","article-title":"Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects","volume":"8","author":"Kong","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_47","first-page":"195","article-title":"Preclinical pharmacology and toxicology of PTC124 as nonsense mutation supression therapy for cystic fibrosis","volume":"38","author":"Du","year":"2004","journal-title":"Ped. Pulm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajmg.a.30617","article-title":"Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort","volume":"134A","author":"Dent","year":"2005","journal-title":"Am. J. Med. Genet. Part. A"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","article-title":"Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy","volume":"31","author":"Grounds","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/CH-16195","article-title":"Circulating serum CK level vs. muscle impairment for in situ monitoring burden of disease in Mdx-mice","volume":"65","author":"Klein","year":"2017","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: A point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2019-0086","article-title":"Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: Patient demographics and characteristics from the STRIDE Registry","volume":"8","author":"Muntoni","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15844\/pedneurbriefs-34-12","article-title":"Treatment with Ataluren for Duchene Muscular Dystrophy","volume":"34","author":"Morkous","year":"2020","journal-title":"Pediatr. Neurol. Briefs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286418809588","article-title":"One-year follow up of three Italian patients with Duchenne musculardystrophy treated with ataluren: Is earlier better?","volume":"11","author":"Ruggiero","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fped.2018.00316","article-title":"Off-Label Use of Ataluren in Four Non-ambulatory Patients with Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength","volume":"6","author":"Dillmann","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_59","first-page":"272","article-title":"Therapeutic approach with Ataluren in Duchenne symptomatic carriers with nonsense mutations in dystrophin gene. Results of a 9-month follow-up in a case report","volume":"37","author":"Orsini","year":"2018","journal-title":"Acta Myol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pauliuc, D., Dranca, F., and Oroian, M. (2020). Antioxidant activity, total phenolic content, individual phenolics and physicochemical parameters suitability for Romanian honey authentication. Foods, 9.","DOI":"10.3390\/foods9030306"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/1357-4310(96)10028-9","article-title":"Understanding how cystic fibrosis mutations cause a loss of Cl- channel function","volume":"2","author":"Sheppard","year":"1996","journal-title":"Mol. Med. Today"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fphar.2012.00117","article-title":"Class 1 CF mutations","volume":"3","author":"Wilschanski","year":"2012","journal-title":"Front. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.1380040302","article-title":"Population variation of common cystic fibrosis mutations","volume":"4","author":"Consortium","year":"1994","journal-title":"Hum. Mutat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/gte.1997.1.35","article-title":"Cystic fibrosis in Jews: Frequency and mutation distribution","volume":"1","author":"Kerem","year":"1997","journal-title":"Genet. Test."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpainsymman.2007.06.005","article-title":"Self-Reported Physical and Psychological Symptom Burden in Adults with Cystic Fibrosis","volume":"35","author":"Sawicki","year":"2008","journal-title":"J. Pain Symptom Manag."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J. Pediatr."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Tietze, K.J. (2012). Review of Laboratory and Diagnostic Tests. Clinical Skills for Pharmacists, Elsevier.","DOI":"10.1016\/B978-0-323-07738-5.10005-5"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Lacomis, D. (2003). Respiratory Dysfunction. Office Practice of Neurology, Elsevier. [2nd ed.].","DOI":"10.1016\/B0-44-306557-8\/50015-0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/humu.1380050106","article-title":"Identification of six mutations (R31L, 441delA, 681delC, 1461ins4, W1089R, E1104X) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene","volume":"5","author":"Zielenski","year":"1995","journal-title":"Hum. Mutat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1183\/09031936.03.00006603","article-title":"Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis","volume":"23","author":"Nakano","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ppul.22991","article-title":"Tracking CF disease progression with CT and respiratory symptoms in a cohort of children aged 6-19 years","volume":"49","author":"Tepper","year":"2014","journal-title":"Pediatric Pulmonol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1164\/rccm.201501-0061OC","article-title":"PRAGMA-CF. A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis","volume":"191","author":"Rosenow","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tiddens, H.A.W.M., Andrinopoulou, E.R., McIntosh, J., Elborn, J.S., Kerem, E., Bouma, N., Bosch, J., and Kemner-Van deCorput, M. (2020). Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240898"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","article-title":"Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)","volume":"19","author":"Konstan","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/ppul.24764","article-title":"Ataluren\/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations","volume":"55","author":"Mutyam","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/1682","article-title":"Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy","volume":"20","author":"Liu","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/archneur.62.8.1256","article-title":"Identification of a novel founder mutation in the DYSF gene causing clinical variability in the spanish population","volume":"62","author":"Vilchez","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/japplphysiol.01366.2009","article-title":"Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression","volume":"109","author":"Wang","year":"2010","journal-title":"J. Appl. Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3892\/ijmm.2013.1601","article-title":"Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome","volume":"33","author":"Yu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-3-18","article-title":"Congenital long QT syndrome","volume":"3","author":"Crotti","year":"2008","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/01.CIR.102.10.1178","article-title":"Spectrum of mutations in Long-QT Syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2","volume":"102","author":"Splawski","year":"2000","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00431-008-0740-z","article-title":"Rab proteins and Rab-associated proteins: Major actors in the mechanism of protein-trafficking disorders","volume":"167","author":"Corbeel","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Moosajee, M., Ramsden, S.C., Black, G.C., Seabra, M.C., and Webster, A.R. (2014). Clinical utility gene card for: Choroideremia. Eur. J. Hum. Genet., 22.","DOI":"10.1038\/ejhg.2013.183"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1471-4914(01)02227-4","article-title":"Rab GTPases, intracellular traffic and disease","volume":"8","author":"Seabra","year":"2002","journal-title":"Trends Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/hmg\/ddu509","article-title":"Translational read-through of the RP2 Arg120stop mutation in patient iPSC-derived retinal pigment epithelium cells","volume":"24","author":"Schwarz","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.604205","article-title":"Phagocytosis by the Retinal Pigment Epithelium: Recognition, Resolution, Recycling","volume":"11","author":"Kwon","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00142-7","article-title":"Rescue of the MERTK phagocytic defect in a human iPSC disease model using translational read-through inducing drugs","volume":"7","author":"Ramsden","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"V\u00f6ssing, C., Owczarek-Lipska, M., Nagel-Wolfrum, K., Reiff, C., J\u00fcschke, C., and Neidhardt, J. (2020). Translational read-through therapy of rpgr nonsense mutations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228418"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archopht.1988.01060130395029","article-title":"X-linked retinitis pigmentosa. Profile of clinical findings","volume":"106","author":"Fishman","year":"1988","journal-title":"Arch. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.matbio.2013.06.003","article-title":"Ectopic mineralization disorders of the extracellular matrix of connective tissue: Molecular genetics and pathomechanisms of aberrant calcification","volume":"33","author":"Li","year":"2014","journal-title":"Matrix Biol."},{"key":"ref_92","first-page":"289","article-title":"The molecular and physiological roles of ABCC6: More than meets the eye","volume":"3","author":"Martin","year":"2012","journal-title":"Front. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/jid.2013.234","article-title":"Premature Termination Codon Read-Through in the ABCC6 Gene: Potential Treatment for Pseudoxanthoma Elasticum","volume":"133","author":"Zhou","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/1098-1004(2001)17:1<34::AID-HUMU4>3.0.CO;2-O","article-title":"Identification of three novel mutations in the USH1C gene and detection of thirty-one polymorphisms used for haplotype analysis","volume":"17","author":"Zwaenepoel","year":"2001","journal-title":"Hum. Mutat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1167\/iovs.03-0483","article-title":"Differential Distribution of Harmonin Isoforms and Their Possible Role in Usher-1 Protein Complexes in Mammalian Photoreceptor Cells","volume":"44","author":"Reiners","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.exer.2005.11.010","article-title":"Molecular basis of human Usher syndrome: Deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease","volume":"83","author":"Reiners","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Samanta, A., Stingl, K., Kohl, S., Nagel-Wolfrum, K., Ries, J., and Linnert, J. (2019). Ataluren for the treatment of usher syndrome 2A caused by nonsense mutations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246274"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/90042","article-title":"PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans","volume":"28","author":"Sisodiya","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI70462","article-title":"Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects","volume":"124","author":"Wang","year":"2014","journal-title":"J. Clin. Invest."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Djayet, C., Bremond-Gignac, D., Touchard, J., Secretan, P.H., Vidal, F., Robert, M.P., Daruich, A., Cisternino, S., and Schlatter, J. (2021). Formulation and stability of ataluren eye drop oily solution for aniridia. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010007"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"s275","DOI":"10.2741\/1049","article-title":"The role of Smads in BMP signaling","volume":"8","author":"Nishimura","year":"2003","journal-title":"Front. Biosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020935783","article-title":"Targeting translational read-through of premature terminationmutations in BMPR2 with PTC124 for pulmonary arterialhypertension","volume":"10","author":"Long","year":"2020","journal-title":"Pulm. Circ."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Dabrowski, M., Bukowy-Bieryllo, Z., Jackson, C.L., and Zietkiewicz, E. (2021). Properties of non-aminoglycoside compounds used to stimulate translational readthrough of ptc mutations in primary ciliary dyskinesia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094923"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semcdb.2020.11.007","article-title":"Motile cilia and airway disease","volume":"110","author":"Legendre","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ajhg.2013.07.025","article-title":"Mutations in SPAG1 cause primary ciliary dyskinesia associated with defective outer and inner dynein arms","volume":"93","author":"Knowles","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","article-title":"The neuronal ceroid-lipofuscinoses","volume":"62","author":"Haltia","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","article-title":"New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses","volume":"79","author":"Williams","year":"2012","journal-title":"Neurology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2011.05.021","article-title":"Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients","volume":"104","author":"Sarkar","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/humu.21624","article-title":"Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses","volume":"33","author":"Kousi","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/ddt596","article-title":"Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway","volume":"23","author":"Lojewski","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_112","first-page":"2035","article-title":"Glycosaminoglycan and collagen metabolism in arylsulfatase B-deficient retinal pigment epithelium in vitro","volume":"32","author":"Stramm","year":"1991","journal-title":"Invest. Ophthalmol Vis. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10545-012-9521-y","article-title":"Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI","volume":"36","author":"Bartolomeo","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2004.02.004","article-title":"Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency","volume":"82","author":"Bennett","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_115","unstructured":"Bennett, M.J., and Santani, A.B. (2021, July 08). Carnitine Palmitoyltransferase 1A Deficiency, GeneReviews\u00ae, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1527\/."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10545-010-9265-5","article-title":"PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation","volume":"34","author":"Tan","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/B978-0-444-64029-1.00022-9","article-title":"Inborn errors of metabolism","volume":"Volume 162","author":"Ferreira","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.20128","article-title":"Molecular basis of methylmalonyl-CoA mutase apoenzyme defect in 40 European patients affected by mut(o) and mut- forms of methylmalonic acidemia: Identification of 29 novel mutations in the MUT gene","volume":"25","author":"Acquaviva","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/humu.22047","article-title":"Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia","volume":"33","author":"Ugarte","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/mt.2013.150","article-title":"A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene","volume":"21","author":"Du","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/gt.2015.7","article-title":"Therapeutic effect of prenatal alkalization and PTC124 in Na+\/HCO3\u2212 cotransporter 1 p.W516* knock-in mice","volume":"22","author":"Fang","year":"2015","journal-title":"Gene Ther."},{"key":"ref_122","first-page":"324","article-title":"Proximal renal tubular acidosis and ocular pathology: A novel missense mutation in the gene (SLC4A4) for sodium bicarbonate cotransporter protein (NBCe1)","volume":"12","author":"Demirci","year":"2006","journal-title":"Mol. Vis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ki.2010.523","article-title":"Severe metabolic acidosis causes early lethality in NBC1 W516X knock-in mice as a model of human isolated proximal renal tubular acidosis","volume":"79","author":"Lo","year":"2011","journal-title":"Kidney Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Beghyn","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1073\/pnas.0909141107","article-title":"Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124","volume":"107","author":"Auld","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.chembiol.2010.05.012","article-title":"Illuminating Insights into Firefly Luciferase and Other Bioluminescent Reporters Used in Chemical Biology","volume":"17","author":"Thorne","year":"2010","journal-title":"Chem. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"McElroy, S.P., Nomura, T., Torrie, L.S., Warbrick, E., Gartner, U., Wood, G., and McLean, W.H.I. (2013). A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays. PLoS Biol., 11.","DOI":"10.1371\/journal.pbio.1001593"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/mp400230s","article-title":"Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay","volume":"11","author":"Lentini","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/acn3.51306","article-title":"Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder","volume":"8","author":"Devinsky","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_132","first-page":"61","article-title":"Dravet Syndrome and SCN1A gene mutations: A review","volume":"10","year":"2020","journal-title":"J. Neurol. Stroke"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1080\/15476286.2019.1632633","article-title":"Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity","volume":"16","author":"Fazzari","year":"2019","journal-title":"RNA Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/humu.10200","article-title":"PAHdb 2003: What a locus-specific knowledgebase can do","volume":"21","author":"Scriver","year":"2003","journal-title":"Hum. Mutat."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10545-013-9602-6","article-title":"In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: A potential therapy for phenylketonuria","volume":"36","author":"Ho","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BJ20111912","article-title":"Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel","volume":"443","author":"Harmer","year":"2012","journal-title":"Biochem. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-011-6352-2","article-title":"The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes","volume":"26","author":"Koopmann","year":"2012","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ymgme.2004.08.008","article-title":"The PEX Gene Screen: Molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum","volume":"83","author":"Steinberg","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/humu.10124","article-title":"Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype","volume":"20","author":"Braverman","year":"2002","journal-title":"Hum. Mutat."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/338998","article-title":"Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1","volume":"70","author":"Motley","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa022050","article-title":"Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene","volume":"348","author":"Farooqi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/er.2009-0037","article-title":"The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology","volume":"31","author":"Tao","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/oby.2011.202","article-title":"Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through","volume":"20","author":"Brumm","year":"2012","journal-title":"Obesity"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51149","article-title":"Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review","volume":"7","author":"Mesas","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_145","unstructured":"US Food and Drug (2021, July 30). Administration Application Number 20688Orig1s000: Summary Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_redacted.pdf."},{"key":"ref_146","unstructured":"(2021, July 29). In Proceedings of the FDA Briefing Document Peripheral and Central Nervous System Drugs Advisory Committee Meeting, Available online: https:\/\/www.fda.gov\/files\/advisory%20committees\/published\/FDA-Briefing-Information-for-the-January-22--2016-Meeting-of-the-Peripheral-and-Central-Nervous-System-Drugs-Advisory-Committee.pdf."},{"key":"ref_147","unstructured":"US Food Drug Administration (2021, July 27). FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/8\/785\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:42:48Z","timestamp":1760164968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/8\/785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":148,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ph14080785"],"URL":"https:\/\/doi.org\/10.3390\/ph14080785","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]}}}